BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.

About this update from Bioporto A/s

[{"type":"image","alt":"BioPorto A/S","displaySize":"","headline":null,"caption":"BioPorto A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XFhYiV2fxrmNbtDA3N3v_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":300,"height":55}},"lazy":false},{"type":"text","content":"August 15, 2025Announcement no. 19","length":35,"tagName":"p"},{"type":"text","content":"BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. ","length":149,"tagName":"p"},{"type":"text","content":"Copenhagen, Denmark, August 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced interim financial results for the second quarter of 2025 and a business update.","length":209,"tagName":"p"},{"type":"text","content":"Continued progress on key strategic milestones for the second quarter of 2025 ","length":77,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Full execution of the objectives outlined in our February 2024 Strategic Plan.","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"A major milestone in the second quarter of 2025 was the receipt of the first purchase order for ProNephroTM AKI (NGAL) for the US market, marking the first step in the commercial launch.","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"The enrollment of patients in the US clinical cut-off study for ProNephro AKI (NGAL) for adult use is progressing as planned and is reaching the final phase. We maintain our goal to submit to the FDA by the end of 2026.","length":219,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":483,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strong NGAL sales growth of 39% compared to the second quarter of 2024.","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"The Board was restructured with Jens Due Olsen stepping in as Chairman and Carsten Buhl appointed as new CEO as of September 1, to drive the next growth phase.","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"O...

More updates from Bioporto A/s